Search

Your search keyword '"Brüggemann, Monika"' showing total 826 results

Search Constraints

Start Over You searched for: Author "Brüggemann, Monika" Remove constraint Author: "Brüggemann, Monika"
826 results on '"Brüggemann, Monika"'

Search Results

1. Die EU-Verordnung für In-vitro-Diagnostika (IVDR) in der Praxis: Umsetzung und Anwendung – Ergebnisse einer öffentlichen Veranstaltung der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) im März 2023

2. Advisory opinion of the AWMF Ad hoc Commission In-vitro Diagnostic Medical Devices regarding in-vitro diagnostic medical devices manufactured and used only within health institutions established in the Union according to Regulation (EU) 2017/746 (IVDR)

3. Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia

4. The gray area of RQ-PCR-based measurable residual disease: subdividing the “positive, below quantitative range” category

5. Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines

6. Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols

10. Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

11. Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma

12. The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis

13. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

14. CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment

15. Virus-reactive T cells expanded in aplastic anemia eliminate hematopoietic progenitor cells by molecular mimicry

16. Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial

18. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

19. Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

20. Struktur und Inhalt der EU-IVDR: Bestandsaufnahme und Implikationen für die Pathologie

22. Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL

23. UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment

25. Long-Term Results of Allogeneic Stem Cell Transplantation in Adult Ph- Negative High-Risk Acute Lymphoblastic Leukemia

26. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial

27. Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL

30. Minimal residual disease assessment in B‐cell precursor acute lymphoblastic leukemia by semi‐automated identification of normal hematopoietic cells: A EuroFlow study.

33. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

34. Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders

36. Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study

37. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1

38. Clinical pilot study on microfluidic automation of IGH-VJ library preparation for next generation sequencing.

39. CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia

40. Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia

43. Dominant T-cell Receptor Delta Rearrangements in B-cell Precursor Acute Lymphoblastic Leukemia: Leukemic Markers or Physiological γδ T Repertoire?

45. The Gene Expression Classifier ALLCatchR Identifies B-cell Precursor ALL Subtypes and Underlying Developmental Trajectories Across Age

46. P352: PROPHYLACTIC AND PREEMPTIVE USE OF DLI COMPARE FAVOURABLY TO THEIR THERAPEUTIC USE IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) – RESULTS OF A MULTICENTRE RETROSPECTIVE STUDY

47. P355: FAVORABLE OUTCOME OF PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WITH IMATINIB, DOSE-REDUCED INDUCTION FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION –RESULTS FROM THE GMALL TRIAL 08/13

49. Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation

50. Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS

Catalog

Books, media, physical & digital resources